I'm LongbridgeAI, I can summarize articles.Autolus Therapeutics reported a narrowed Q2 net loss of $39.1 million and doubled net product revenue to $45.7 million, driven by rising demand. Gross margin improved to 55%, and operating loss decreased. The company raised its FY2026 net product revenue outlook to $140-$150 million, citing strong enthusiasm for AUCATZYL and on-track trials for obe-cel.
- Autolus posted Q2 net product revenue of $45.7 million, more than doubled year over year, lifted by rising demand and new centers. * Gross margin swung to 55% from 6% in Q1, reflecting lower manufacturing cost per batch and fewer inventory reserves. * Operating loss narrowed to $43.8 million; net loss improved to $39.1 million, or $(0.15) per share. * FY 2026 net product revenue outlook rose to $140 million-$150 million; cash and marketable securities were $201.6 million at June 30. * Autolus cited strong physician enthusiasm for AUCATZYL, targeting 65%-70% peak adult ALL margins; obe-cel trials in lupus, pediatric ALL and progressive MS remained on track. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807607) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)